5/15
09:19 am
lucd
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
Medium
Report
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
5/13
12:16 pm
lucd
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
Low
Report
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
5/13
08:09 am
lucd
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results [Yahoo! Finance]
5/13
08:00 am
lucd
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
Medium
Report
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
5/9
08:04 am
lucd
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall [Yahoo! Finance]
Medium
Report
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall [Yahoo! Finance]
5/9
07:49 am
lucd
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
Low
Report
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
5/7
07:44 am
lucd
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors [Yahoo! Finance]
Medium
Report
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors [Yahoo! Finance]
5/7
07:39 am
lucd
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
Medium
Report
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
5/2
08:35 am
lucd
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
Medium
Report
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
5/2
07:56 am
lucd
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing [Yahoo! Finance]
Medium
Report
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing [Yahoo! Finance]
5/2
07:49 am
lucd
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
Medium
Report
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
4/29
08:47 am
lucd
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
High
Report
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
4/12
08:02 am
lucd
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
Medium
Report
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
4/8
08:30 am
lucd
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
3/27
12:40 pm
lucd
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/27
10:08 am
lucd
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its price target lowered by analysts at Cantor Fitzgerald from $3.80 to $3.00. They now have an "overweight" rating on the stock.
Low
Report
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its price target lowered by analysts at Cantor Fitzgerald from $3.80 to $3.00. They now have an "overweight" rating on the stock.
3/27
08:09 am
lucd
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
Low
Report
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
3/25
05:42 pm
lucd
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/25
05:30 pm
lucd
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
Medium
Report
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
3/21
09:38 am
lucd
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population [Yahoo! Finance]
Medium
Report
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population [Yahoo! Finance]
3/21
09:30 am
lucd
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Medium
Report
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
3/20
08:30 am
lucd
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
Low
Report
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
3/12
08:30 am
lucd
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
Low
Report
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
3/3
10:30 am
lucd
Health's weekend read includes kidney donations, cancer prevention, measles vaccinations and more [FOX News]
Medium
Report
Health's weekend read includes kidney donations, cancer prevention, measles vaccinations and more [FOX News]